following a resubmission
axitinib (Inlyta®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
In a phase III, open-label study, axitinib improved progression-free survival significantly more than another targeted therapy when used after first-line sunitinib or a cytokine. There was no significant improvement in overall survival.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of axitinib. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice175KB (PDF)
Medicine details
- Medicine name:
- axitinib (Inlyta)
- SMC ID:
- 855/13
- Indication:
- For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 11 November 2013